Literature DB >> 16286165

Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study.

Paul A Gurbel1, Kevin P Bliden, Kirk Guyer, Peter W Cho, Kazi A Zaman, Rolf P Kreutz, Ashwani K Bassi, Udaya S Tantry.   

Abstract

OBJECTIVES: We investigated the relation of high ex vivo platelet reactivity, rapid fibrin generation, and high thrombin-induced clot strength to postdischarge ischemic events in patients undergoing percutaneous coronary intervention (PCI).
BACKGROUND: High platelet reactivity and rapid fibrin generation may affect the incidence of ischemic events after PCI. However, limited data is available to link these ex vivo markers to the occurrence of events.
METHODS: We measured platelet reactivity to adenosine diphosphate (ADP) by light transmittance aggregometry (LTA) in patients undergoing PCI (n = 192). Clot strength, a measure of thrombin-induced fibrin and platelet interactions, and the time to initial fibrin generation, a marker of thrombin activity, were measured by thrombelastography. The relation of these measurements to ischemic event occurrence was prospectively examined over six months.
RESULTS: A total of 100% and 84% of patients were on aspirin and clopidogrel therapy, respectively, at the time of the initial event. Posttreatment ADP-induced aggregation by LTA (63 +/- 12% vs. 56 +/- 15%, p = 0.02) and clot strength (MA) were higher (74 +/- 5 mm vs. 65 +/- 4 mm, p < 0.001) and time to initial fibrin generation was shorter (4.3 +/- 1.3 min vs. 5.9 +/- 1.5 min, p < 0.001) in patients with events (n = 38). The event rates in the highest quartiles of LTA and MA were 32% and 58%, respectively.
CONCLUSIONS: High platelet reactivity and clot strength, and rapid fibrin formation are novel risk factors for ischemic events after PCI. Clot strength is more predictive than ADP-induced platelet aggregation and may explain the occurrence of events despite treatment with cyclooxygenase-1 and P2Y12 inhibitors.

Entities:  

Mesh:

Year:  2005        PMID: 16286165     DOI: 10.1016/j.jacc.2005.07.041

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  111 in total

1.  Frequency of heparin/platelet factor 4-dependent platelet antibodies in patients undergoing angioplasty and stenting for cardiovascular disease and their role for on-clopidogrel platelet reactivity.

Authors:  Thomas Gremmel; Karin Frühwirth; Christoph W Kopp; Alexandra Kaider; Sabine Steiner; Tamam Bakchoul; Ulrich J H Sachs; Renate Koppensteiner; Simon Panzer
Journal:  Clin Res Cardiol       Date:  2012-01-11       Impact factor: 5.460

2.  Immature platelet fraction (IPF) determined with an automated method predicts clopidogrel hyporesponsiveness.

Authors:  Homam Ibrahim; Srinivas Nadipalli; Timothy DeLao; Sasidhar Guthikonda; Neal S Kleiman
Journal:  J Thromb Thrombolysis       Date:  2012-02       Impact factor: 2.300

3.  Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y12 assay.

Authors:  In-Suk Kim; Young-Hoon Jeong; Min-Kyung Kang; Jin-Sin Koh; Yongwhi Park; Seok-Jae Hwang; Choong Hwan Kwak; Jin-Yong Hwang; Sunjoo Kim
Journal:  J Thromb Thrombolysis       Date:  2010-11       Impact factor: 2.300

Review 4.  Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implications.

Authors:  Stavros Spiliopoulos; Georgios Pastromas
Journal:  World J Cardiol       Date:  2015-12-26

5.  Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease.

Authors:  Paul A Gurbel; Kevin P Bliden; Susan E Turner; Udaya S Tantry; Martin G Gesheff; Travis P Barr; Lidija Covic; Athan Kuliopulos
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-01       Impact factor: 8.311

6.  High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study.

Authors:  Amala P Chirumamilla; Akiko Maehara; Gary S Mintz; Roxana Mehran; Sunil Kanwal; Giora Weisz; Ahmed Hassanin; Diaa Hakim; Ning Guo; Usman Baber; Robert Pyo; Jeffrey W Moses; Martin Fahy; Jason C Kovacic; George D Dangas
Journal:  JACC Cardiovasc Imaging       Date:  2012-05

Review 7.  High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance.

Authors:  Torkom Garabedian; Samir Alam
Journal:  Cardiovasc Diagn Ther       Date:  2013-03

8.  Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting.

Authors:  S Prabhakaran; K R Wells; V H Lee; C A Flaherty; D K Lopes
Journal:  AJNR Am J Neuroradiol       Date:  2007-11-07       Impact factor: 3.825

9.  Fibrinogen beta-chain tyrosine nitration is a prothrombotic risk factor.

Authors:  Ioannis Parastatidis; Leonor Thomson; Anne Burke; Irina Chernysh; Chandrasekaran Nagaswami; Jetze Visser; Sheryl Stamer; Daniel C Liebler; George Koliakos; Harry F G Heijnen; Garret A Fitzgerald; John W Weisel; Harry Ischiropoulos
Journal:  J Biol Chem       Date:  2008-09-25       Impact factor: 5.157

Review 10.  Monitoring aspirin and clopidogrel response: testing controversies and recommendations.

Authors:  Athanasios Karathanos; Tobias Geisler
Journal:  Mol Diagn Ther       Date:  2013-06       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.